Therapy Areas: AIDS & HIV
Celgene Corp. Announces Pomalyst Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma
...
Gilead Sciences to Provide Free Truvada for PrEP to Support US Initiative to End the HIV Epidemic
15 May 2019 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the...
USFDA grants breakthrough therapy designation to Celgene's Pomalyst
15 May 2019 - It was reported yesterday that the US Food and Drug Administration (USFDA) has granted breakthrough therapy designation to United States-based Celgene's Pomalyst (pomalidomide) inte...
ViiV Healthcare seeks US FDA approval for two-drug HIV treatment
1 May 2019 - United Kingdom-based ViiV Healthcare is seeking approval from the US Food and Drug Administration (FDA) for the investigational, monthly, injectable, two-drug regimen of cabotegravir and ...
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
30 April 2019 - - UK-based specialist HIV company ViiV Healthcare, which is majority owned by GSK, with Pfizer Inc. and Shionogi Ltd. as shareholders, has submitted a New Drug Application to the US Fo...
CDISC, C-Path Develop Therapeutic Area Standard to Foster More Efficient and Meaningful Research for HIV
18 April 2019 - - US-based nonprofit charitable organisation CDISC and the nonprofit organization Critical Path Institute (C-Path) have released a global Therapeutic Area Standard that specifies how t...